Our Team
The organization continually enhances operational and quality frameworks, empowering its team to ensure absolute customer satisfaction through rigorous validation of products and processes. With well-equipped facilities and a commitment to automated workflows where beneficial, the company maintains stringent quality standards upheld by a competent and innovative team.
Our Team
The organization continually enhances operational and quality frameworks, empowering its team to ensure absolute customer satisfaction through rigorous validation of products and processes. With well-equipped facilities and a commitment to automated workflows where beneficial, the company maintains stringent quality standards upheld by a competent and innovative team.
Board Of Directors
The Board of Directors will oversee the company's strategic direction, organizational structure, and administrative functions.

David Goodman
Board member

James Gale
Executive Chairman Of The Board
James (Jim) Gale is the founding partner of Signet Healthcare Partners. Jim has over 35 years of healthcare investing and finance experience.
He is currently the Chairman of the Board of Bionpharma, Inc; lead director of Knight Therapeutics Inc. (TSX: GUD); and also serves on the Board of Directors of the following Signet portfolio companies: Juno Pharmaceuticals Corp, Chr. Olesen Synthesis A/S, Pharmaceutics International (Pii), RK Pharma, and Ascendia Pharmaceuticals. He also serves on the Board of Hyloris Pharmaceuticals SA (Euronext: HYL) and Cerium Pharmaceuticals. Prior portfolio company Boards include: Advantice Health (acquired by TA Associates), Arbor Pharmaceuticals, Amarin Corporation, eResearch Technologies Inc., Teligent Inc, and Valera Pharmaceuticals.
Prior to founding Signet, Jim was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, he made a number of investments including Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation (now part of AbbVie), Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).
Prior to joining Gruntal, he originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent. Earlier in his career, Jim was a senior investment banker at E.F. Hutton & Co.
Jim received his Masters of Business Administration from the University of Chicago.

Venkat Krishnan
Board member

Richard Van Duyne
Board member

Carole Ben-Maimon, M.D.
President And Chief Executive Officer
Executive Team
The leadership has the responsibility of managing the business operations of Bionpharma.

Venkat Krishnan
Board member

Lavesh Samtani, Esq.
EVP Business Development and General Counsel

Lavesh Samtani, Esq.
EVP Business Development and General Counsel

Gaurav Mehrotra
CFO & EVP Commercial Operations

Gaurav Mehrotra
CFO & EVP Commercial Operations

Phanindranath "Nath" Punji
EVP Supply Chain & Projects

Phanindranath "Nath" Punji
EVP Supply Chain & Projects
Investors

Pharma Science
Our other strategic partner is Pharmascience Inc. Founded in 1983, Pharmascience is a leading manufacturer of generic drugs in a wide range of therapeutic categories. They are a privately owned company with technologically sophisticated operations designed to satisfy customer expectations for quality products and responsive service . Pharmascience’s R & D laboratory and production facilities are located in Montreal, Quebec and their Canada-wide customer base includes pharmacists, drug wholesalers and major retailers. Pharmacience is the largest pharmaceutical employer in Quebec, Canada, with 1,300 employees and the third largest generic pharmaceutical company in Canada and third largest pharmaceutical company in Canada by number of prescriptions. Pharmascience enjoys a diversified portfolio of over 340 product families, both prescription and OTC with sales in more than 60 countries and is one of the largest providers of generic single-source products.

Athyrium
LP: Athyrium Capital Management LP is an SEC-registered asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Managing funds with over $1.7 billion of committed capital, including a $1.2 billion fund recently closed in May 2015 , Athyrium invests across all healthcare verticals including biopharmaceuticals, medical devices and products, and healthcare services. The Athyrium team has substantial investment experience in the healthcare sector across a wide range of asset classes, including private equity, public equity, fixed income, royalties, and other structured securities. The firm’s investors include public and corporate pension funds, charitable endowments, insurance companies, funds-of-funds, family offices, university endowments, and sovereign wealth funds.

Signet
Signet Healthcare partners was founded in 1998 with the establishment of the Corporate Opportunities Funds. Since 1998, they have organized three funds and completed investments in approximately 35 companies. The team is comprised of six professionals with principal offices in New York City. This team brings over 100 years experience of collective healthcare experience in the specialty pharmaceutical, medical device, private equity and investment banking businesses. For the past sixteen years, Signet Healthcare has maintained its dedicated focus to diversified healthcare investing – primarily serving as lead investor to expansion stage companies engaged in specialty pharmaceuticals, medical devices and the pharma services industries.